Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Chau on CheckMate577 Study in Esophageal/GEJ Cancer

Ian Chau, MD
Published: Thursday, Mar 09, 2017



Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the CheckMate 577 study in resected lower esophageal or gastroesophageal junction (GEJ) cancer.

CheckMate 577 is a randomized, double-blind, phase III study of nivolumab (Opdivo) in the adjuvant setting. Patients with stage I/II esophageal or GEJ cancer that have undergone preoperative chemoradiotherapy (CRT) are randomized to receive either nivolumab or placebo. This is due to the increase in expression of PD-L1 after CRT, says Chau, which has demonstrated survival benefits when combined with nivolumab.

This study is ongoing, with primary endpoints of overall survival and disease-free survival.
 


Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the CheckMate 577 study in resected lower esophageal or gastroesophageal junction (GEJ) cancer.

CheckMate 577 is a randomized, double-blind, phase III study of nivolumab (Opdivo) in the adjuvant setting. Patients with stage I/II esophageal or GEJ cancer that have undergone preoperative chemoradiotherapy (CRT) are randomized to receive either nivolumab or placebo. This is due to the increase in expression of PD-L1 after CRT, says Chau, which has demonstrated survival benefits when combined with nivolumab.

This study is ongoing, with primary endpoints of overall survival and disease-free survival.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Archived Version of a Live Webcast: Virtual Current Trends™: Global Perspectives on Emerging Data in Hepatocellular CarcinomaMay 31, 20192.0
Publication Bottom Border
Border Publication
x